(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Vote in favor of your Favored Travel Movement - 2Geminid shooting stars: One of 2025's most exciting meteor showers begins tonight
- 3Women take pride in Holy Week roles after a Spanish Catholic brotherhood's procession excluded them
- 4Lego's $650 Pokémon set is already sold out as demand, preorders surge
- 5Argentina joins NASA’s moon return with microsatellite testing GPS beyond Earth
- How did I get my own unique set of fingerprints?
- Germany's first Omani LNG shipments arrive despite Middle East disruptions
- Joshua Made Last-Second Seat Change That Saved His Life
- Pedal Power: Divulging Well known Bike Brands for Each Cyclist
- Top 10 Smash hit Computer games of the Year
- King Charles shares cancer treatment update, says it's a 'personal blessing'
- Vote in favor of Your Number one Cake Type
- 7 Powerful Methods for forestalling Telephone Overheating: Keep Your Gadget Cool
- Which game do you cherish observing live? Vote!
